Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GABITRIL · 5 trials · 4 indications
| Name | Type | Description |
|---|---|---|
| Gabitril | DRUG | - |
| GABITRIL (tiagabine hydrochloride; CEP-6671) | DRUG | - |
Subjects who have completed 10 weeks of double-blind treatment and the subsequent taper period in 1 of the 3 previous double-blind studies (studies C6671/3030/AX/US, C6671/3031/AX/US, or C6671/3032/AX/US).
GABITRIL is a small molecule being studied for the treatment of generalized anxiety disorder in adults. It is an investigational drug in Phase 3 clinical development and has not been approved by the FDA. Clinical trials have evaluated its safety and efficacy in patients with generalized anxiety disorder.
GABITRIL is being developed by Teva Pharmaceutical Industries Limited, a company publicly traded under the ticker TEVA. The drug is currently in Phase 3 clinical trials for generalized anxiety disorder, with studies conducted in the United States and Canada.
GABITRIL is in Phase 3 clinical development for the treatment of generalized anxiety disorder. It is an investigational drug, meaning it has not received FDA approval. Several Phase 3 trials have been completed to evaluate its safety and efficacy in adult patients.
GABITRIL has been studied in multiple Phase 3 clinical trials, including NCT00233675, NCT00236015, NCT00236054, and NCT00236067. These trials evaluated the safety and efficacy of GABITRIL in adults with generalized anxiety disorder. All trials have been completed, with total enrollment across studies reaching 880 participants.
GABITRIL is not FDA approved. It is an investigational drug currently in Phase 3 clinical trials for generalized anxiety disorder. The completed trials have assessed its safety and efficacy, but regulatory approval has not been granted.